

roup Corporation submitted "Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of r

Top

Search

Result

Company

Watchlist

Our message

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. [2395] [E05385]

Basic Info

Summary

Highlights

Financial Statements

Profit Analysis

Ranking

Fiscal year:

2018

☐ Q1☐ Q2☐ Q3☒ Y/E☒ US\$☐ Yen[Download\(.xls\)](#)

## Financial Statements (Consolidated)

FY03/2018

BS

P/L

CI

SS

CF

Consolidated P/L

(\$)

	Previous year (From Apr 1, 2016 To Mar 31, 2017)	Current year (From Apr 1, 2017 To Mar 31, 2018)
Net sales	153,707,960	156,255,177
Cost of sales	114,843,114	107,270,501
Gross profit	38,864,845	48,984,676
Selling, general and administrative expenses		
Directors' compensations	2,302,362	2,594,512
Salaries and allowances	17,822,792	17,715,230
Retirement benefit expenses	318,504	169,512
Welfare expenses	3,020,037	2,981,617
Insurance expenses	257,679	279,123
Supplies expenses	640,521	778,944
Rent expenses	1,148,578	1,224,191
Depreciation	2,240,217	2,301,675
Traveling, transportation and vehicle expenses	1,778,492	1,754,537
Commission fee	6,392,513	5,717,639
Bleeding animal maintenance expenses	5,323,763	5,340,173
Research and development expenses	5,353,445	4,879,471
Provision of allowance for doubtful accounts	62,670	129,179
Other	8,180,640	9,683,857
Total selling, general and administrative expenses	54,842,259	55,549,736
Operating loss	-15,977,413	-6,565,051
Non-operating income		
Interest income	134,602	85,345
Dividend income	21,891	0
Foreign exchange gains	252,678	-
Gain on sales of investment securities	685,774	-
Rent income	846,020	661,446

Share of profit of entities accounted for using equity method	107,799	6,004,217
Subsidy income	78,545	81,551
Other	912,586	1,191,011
Total non-operating income	3,039,932	8,023,588
Non-operating expenses		
Interest expenses	3,370,318	3,520,369
Foreign exchange losses	-	4,023,701
Commission fee	1,913,138	1,328,633
Other	546,537	239,072
Total non-operating expenses	5,830,003	9,111,785
Ordinary loss	-18,767,484	-7,653,247
Extraordinary income		
Gain on sales of non-current assets	61,218	16,858
Gain on change in equity	6,992,031	1,283,763
Gain on sales of investment securities	1,420,162	1,723
Gain on sales of shares of subsidiaries and associates	4,153,917	3,207,991
Other	319,244	12,321
Total extraordinary income	12,946,591	4,522,694
Extraordinary losses		
Loss on sales of non-current assets	23,095	2,231
Loss on retirement of non-current assets	53,659	547,769
Impairment loss	105,562	2,051,167
Settlement package	-	1,639,778
Loss on valuation of investment securities	246,894	-
Loss on sales of shares of subsidiaries and associates	484,713	6,562,604
Other	81,210	260,081
Total extraordinary losses	995,151	11,063,658
Loss before income taxes	-6,816,044	-14,194,211
Income taxes - current	1,635,975	914,307
Income taxes - deferred	-497,005	18,035,552
Total income taxes	1,138,970	18,949,859
Loss	-7,955,014	-33,144,079
Profit attributable to non-controlling interests	209,154	326,817
Loss attributable to owners of parent	-8,164,168	-33,470,896

This financial information has been prepared by Internet Disclosure Co., Ltd. based on XBRL data delivered by TDnet. Conversion is done using year-end closing rates. These contents have been produced with the utmost care. However, we bear no responsibility for content errors.

All intellectual property rights relating to information in our database belong to Internet Disclosure, and the providers of the information  
Some of our information is provided by the Tokyo Stock Exchange.  
Copyright © 2011. Internet Disclosure Co., Ltd. All Rights Reserved.

